{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:51:33Z","timestamp":1791276693170,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01277-0","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:00:31Z","timestamp":1791230431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of Brain Physiologically Based Pharmacokinetic Modeling in Support of CNS Drug Development: Case Example of Fenebrutinib"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-6675","authenticated-orcid":false,"given":"Christine M.","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8589-0206","authenticated-orcid":false,"given":"Fang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4732","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-9572","authenticated-orcid":false,"given":"Denison","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0951-5835","authenticated-orcid":false,"given":"Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4020-6149","authenticated-orcid":false,"given":"Matthew R.","family":"Durk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-0658","authenticated-orcid":false,"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1002\/jps.23266","volume":"101","author":"K Ball","year":"2012","unstructured":"Ball K, Bouzom F, Scherrmann J, Walther B, Decl\u00e8ves X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro\u2013in vivo scaling methodology for the blood\u2013brain barrier permeability of two transporter substrates, morphine and oxycodone. J Pharm Sci. 2012;101:4277\u201392. https:\/\/doi.org\/10.1002\/jps.23266.","journal-title":"J Pharm Sci"},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.dmpk.2016.03.005","volume":"31","author":"L Gaohua","year":"2016","unstructured":"Gaohua L, Neuhoff S, Johnson TN, Rostami-Hodjegan A, Jamei M. Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: estimating time varying CSF drug concentrations and their variability using in vitro data. Drug Metab Pharmacokinet. 2016;31:224\u201333. https:\/\/doi.org\/10.1016\/j.dmpk.2016.03.005.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1277_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.xphs.2015.12.005","volume":"105","author":"PE Trapa","year":"2016","unstructured":"Trapa PE, Belova E, Liras JL, Scott DO, Steyn SJ. Insights from an integrated physiologically based pharmacokinetic model for brain penetration. J Pharm Sci. 2016;105:965\u201371. https:\/\/doi.org\/10.1016\/j.xphs.2015.12.005.","journal-title":"J Pharm Sci"},{"key":"1277_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejps.2017.11.011","volume":"112","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, V\u00e4litalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, et al. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. Eur J Pharm Sci. 2018;112:168\u201379. https:\/\/doi.org\/10.1016\/j.ejps.2017.11.011.","journal-title":"Eur J Pharm Sci"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1124\/jpet.107.130294","volume":"325","author":"X Liu","year":"2008","unstructured":"Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008;325:349\u201356. https:\/\/doi.org\/10.1124\/jpet.107.130294.","journal-title":"J Pharmacol Exp Ther"},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.111.180398","volume":"339","author":"H Kodaira","year":"2011","unstructured":"Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther. 2011;339:935\u201344. https:\/\/doi.org\/10.1124\/jpet.111.180398.","journal-title":"J Pharmacol Exp Ther"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","volume":"40","author":"ECM de Lange","year":"2013","unstructured":"de Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40:315\u201326. https:\/\/doi.org\/10.1007\/s10928-013-9301-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/bdd.2344","volume":"44","author":"C Bowman","year":"2023","unstructured":"Bowman C, Ma F, Mao J, Plise E, Chen E, Liu L, et al. Evaluation of bottom\u2010up modeling of the blood\u2013brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2023;44:60\u201370. https:\/\/doi.org\/10.1002\/bdd.2344.","journal-title":"Biopharm Drug Dispos"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/s1474-4422(25)00174-7","volume":"24","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Dufek M, Budincevic H, Drulovic J, Habek M, Hua LH, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24:656\u201366. https:\/\/doi.org\/10.1016\/s1474-4422(25)00174-7.","journal-title":"Lancet Neurol"},{"key":"1277_CR10","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1021\/acs.molpharmaceut.8b00688","volume":"15","author":"EC Chen","year":"2018","unstructured":"Chen EC, Broccatelli F, Plise E, Chen B, Liu L, Cheong J, et al. Evaluating the utility of canine Mdr1 knockout Madin-Darby canine kidney I cells in permeability screening and efflux substrate determination. Mol Pharm. 2018;15:5103\u201313. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00688.","journal-title":"Mol Pharm"},{"key":"1277_CR11","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1016\/j.xphs.2020.06.029","volume":"109","author":"C Leung","year":"2020","unstructured":"Leung C, Kenny JR, Hop CECA, Yan Z. Strategy for determining the free fraction of labile covalent modulators in plasma using equilibrium dialysis. J Pharm Sci. 2020;109:3181\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2020.06.029.","journal-title":"J Pharm Sci"},{"key":"1277_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, et al. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2022;15:442\u201350. https:\/\/doi.org\/10.1111\/cts.13162.","journal-title":"Clin Transl Sci"},{"key":"1277_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/psp4.12515","volume":"9","author":"Y Chen","year":"2020","unstructured":"Chen Y, Ma F, Jones NS, Yoshida K, Chiang P, Durk MR, et al. Physiologically\u2010based pharmacokinetic model\u2010informed drug development for fenebrutinib: understanding complex drug\u2010drug interactions. CPT Pharmacomet Syst Pharmacol. 2020;9:332\u201341. https:\/\/doi.org\/10.1002\/psp4.12515.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cpt.1599","volume":"107","author":"NS Jones","year":"2020","unstructured":"Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clin Pharmacol Ther. 2020;107:269\u201377. https:\/\/doi.org\/10.1002\/cpt.1599.","journal-title":"Clin Pharmacol Ther"},{"key":"1277_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0983","author":"J Li","year":"2017","unstructured":"Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, et al. Quantitative and mechanistic understanding of AZD1775 penetration across human blood-brain barrier in glioblastoma patients using an IVIVE-PBPK modeling approach. Clin Cancer Res. 2017. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0983.","journal-title":"Clin Cancer Res"},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/157340906776056437","volume":"2","author":"J Luco","year":"2006","unstructured":"Luco J, Marchevsky E. QSAR studies on blood-brain barrier permeation. Curr Comput Aided Drug Des. 2006;2:31\u201355. https:\/\/doi.org\/10.2174\/157340906776056437.","journal-title":"Curr Comput Aided Drug Des"},{"key":"1277_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.55782\/ane-2008-1708","volume":"68","author":"J Skipor","year":"2008","unstructured":"Skipor J, Thiery J-C. The choroid plexus--cerebrospinal fluid system: undervaluated pathway of neuroendocrine signaling into the brain. Acta Neurobiol Exp. 2008;68:414\u201328. https:\/\/doi.org\/10.55782\/ane-2008-1708.","journal-title":"Acta Neurobiol Exp"},{"key":"1277_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11095-006-9135-x","volume":"24","author":"JC Kalvass","year":"2007","unstructured":"Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res. 2007;24:265\u201376. https:\/\/doi.org\/10.1007\/s11095-006-9135-x.","journal-title":"Pharm Res"},{"key":"1277_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-020-00191-7","volume":"17","author":"MJ Workman","year":"2020","unstructured":"Workman MJ, Svendsen CN. Recent advances in human iPSC-derived models of the blood\u2013brain barrier. Fluids Barriers CNS. 2020;17:30. https:\/\/doi.org\/10.1186\/s12987-020-00191-7.","journal-title":"Fluids Barriers CNS"},{"key":"1277_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/jnc.13147","volume":"134","author":"Y Uchida","year":"2015","unstructured":"Uchida Y, Zhang Z, Tachikawa M, Terasaki T. Quantitative targeted absolute proteomics of rat blood\u2013cerebrospinal fluid barrier transporters: comparison with a human specimen. J Neurochem. 2015;134:1104\u201315. https:\/\/doi.org\/10.1111\/jnc.13147.","journal-title":"J Neurochem"},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/jcbfm.2009.200","volume":"30","author":"M Frid\u00e9n","year":"2009","unstructured":"Frid\u00e9n M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab. 2009;30:150\u201361. https:\/\/doi.org\/10.1038\/jcbfm.2009.200.","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01277-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:03:16Z","timestamp":1791273796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01277-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01277-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"164"}}